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Abstract
Worldwide use of formalin-fixed paraffin-embedded blocks (FFPE) is extensive in diagnosis
and research. Yet, there is a lack of optimized/standardized protocols to process the blocks
and verify the quality and presence of the targeted tissue. In the context of an international
study on head and neck cancer (HNC)—HPV-AHEAD, a standardized protocol for optimiz-
ing the use of FFPEs in molecular epidemiology was developed and validated. First, a proto-
col for sectioning the FFPE was developed to prevent cross-contamination and distributed
between participating centers. Before processing blocks, all sectioning centers underwent a
quality control to guarantee a satisfactory training process. The first and last sections of the
FFPEs were used for histopathological assessment. A consensus histopathology evaluation
form was developed by an international panel of pathologists and evaluated for four indica-
tors in a pilot analysis in order to validate it: 1) presence/type of tumor tissue, 2) identification
of other tissue components that could affect the molecular diagnosis and 3) quality of the
tissue. No HPV DNA was found in sections from empty FFPE generated in any histology
laboratories of HPV-AHEAD consortium and all centers passed quality assurance for pro-
cessing after quality control. The pilot analysis to validate the histopathology form included
355 HNC cases. The form was filled by six pathologists and each case was randomly
assigned to two of them. Most samples (86%) were considered satisfactory. Presence of
>50% of invasive carcinoma was observed in all sections of 66% of cases. Substantial
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necrosis (>50%) was present in <2% of samples. The concordance for the indicators tar-
geted to validate the histopathology form was very high (kappa > 0.85) between first and
last sections and fair to high between pathologists (kappa/pabak 0.21–0.72). The protocol
allowed to correctly process without signs of contamination all FFPE of the study. The histo-
pathology evaluation of the cases assured the presence of the targeted tissue, identified the
presence of other tissues that could disturb the molecular diagnosis and allowed the assess-
ment of tissue quality.
Introduction
In the last decade an enormous number of molecular biology techniques have been developed,
allowing for analysis of a wide spectrum of biomarkers in human specimens. Importantly, this
high throughput technology permits the design of retrospective studies that are based on the
use of archived material, such as formalin-fixed paraffin-embedded (FFPE) tissue samples.
The conduction of worldwide multicenter studies using FFPE tissue samples has become a
common practice in molecular epidemiology [1–6]. Yet, there is a lack of optimized and stan-
dardized protocols on how to process the archived FFPE tissue samples. In the case of molecu-
lar epidemiological studies, FFPE tissue blocks are processed by a broad spectrum of different
procedures such as extraction of nucleic acids, immunohistochemistry (IHC) or in situ hybrid-
ization (ISH) analyses. For molecular studies, it is critical to avoid sample cross-contamination
during the processing (e.g. sectioning) of the FFPE tissue blocks and to obtain the highest qual-
ity of the specimens in order to perform all laboratory assays. The validation of the original his-
topathological diagnosis is essential to ensure that the study specimens correspond to the
pathology targeted by the study and that there is sufficient representation.
Studies aiming to estimate the attributable fractions (AFs) of infections-related cancers in
different geographical areas are nowadays frequent. Relevant examples are the studies on
mucosal high-risk (HR) human papillomaviruses (HPV) that are associated with cervical can-
cer and a proportion of other ano-genital cancers and oropharyngeal cancers [1–6]. In such
studies, where highly sensitive assays are being used to assure the existence of invasive tumor
in the paraffin curl to be tested for HPV DNA and/or mRNA, cross contamination is particu-
larly a concern to avoid false positive results. It is also crucial to address how to avoid false neg-
ative results. This is especially relevant in head and neck cancer (HNC) studies and other
tumor locations in which biopsies are usually small and the probabilities of missing relevant
tissue are high. Ensuring the presence of malignant cells in the curl is important to avoid run-
ning the test on premalignant cells often seen in adjacent infiltrating tissue.
We have recently conducted a HNC case study that involved many centers in Europe and
India, i.e. “Role of human papillomavirus infection and other co-factors in the aetiology of
head and neck cancer in Europe and India” (HPV-AHEAD). The HPV-AHEAD consortium
comprised nine partners from six European countries (Belgium, France, Germany, Greece,
Italy and Spain) and one partner from India [7,8]. The main goal of the study was to perform a
comprehensive analysis on a large number of HNC cases to provide important insights on the
aetiology of HNC and further clarify the role of HPV infection in the disease.
Due to the multi-centric nature of the study, it was essential to develop several standardized
protocols to efficiently achieve the planned goal. These protocols were to be performed simul-
taneously in different centres in Europe and India and included processing of human speci-
mens for the several laboratory assays and the histopathologic review of the cases. In order to
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validate the standardization of the protocols, two main objectives were established. The first
one was to assure that there had not been contamination when sectioning the blocks at the dif-
ferent centers. The second one was to confirm that the histopathology evaluation form devel-
oped by an international panel of pathologists could: 1) assure the presence of the tumor
tissue, 2) identify other tissues that could invalidate the diagnosis of interest (e.g. normal or
pre-neoplastic tissue) and 3) validly assess the quality of the tissue. Here, we describe all proto-
cols and procedures for the processing of the archived FFPE tissue specimens that have been
developed in the context of the HPV-AHEAD consortium and that can be adopted by other
multicentric studies. We also report the results of a pilot study on the achievement of the
objectives to validate it.
Material and methods
Protocol for sectioning of the cases
One of the major goals of the HPV-AHEAD study was to collect approximately 8000 FFPE
HNCs in Europe and India and to determine the possible presence of HPV and cellular gene
transcripts expression by different laboratory assays. Due to the fact that several collecting cen-
ters could not deliver the FFPE blocks to central lab of the project at the International Agency
for Cancer Research (IARC), we developed a protocol for FFPE sectioning that was distributed
to the collecting centers. The protocol describes the generation of several sections for labora-
tory assays and histological analyses, as schematically shown in Fig 1 and with more detail in
Fig 2 where steps S1-S17 are described.
Only specimens fixed in neutral buffered formalin were included in the study. Specimens
fixed in Bouin were not considered suitable for the study and thus excluded since the acidic
environment of this fixative is a major cause for DNA degradation and makes extraction very
difficult [9]. The total number of sections to be done in each block was established at 31. When
the size of the tissue was the limiting factor, sectioning could be stopped after S10 (indicated
by the arrows in Fig 1); otherwise the sectioning could progress until S31. The sections S1, S10
and S31 were used for histopathological assessment after haematoxylin and eosin staining. The
use of the first and last section for confirmative histology was the most important aspect of sec-
tioning, as it would guarantee that all analyses of the in-between sections were performed on
the targeted cancer tissue. The second (S2) and semi-last (S9) sections were intended for
p16INK4a immunohistochemistry (IHC) analysis; The slides to be used for viral DNA and RNA
were optimally chosen as those in between the slides for histology and p16INK4a staining: the
S3 to S5 sections for HPV mRNA analysis; the S6 to S8 sections for detection of and genotyp-
ing HPV DNA. If there was sufficient material, additional slides (S11-S30) were generated for
additional IHC and real-time RT-PCR analyses with other cellular proteins. The procedure
was well validated in the context of the HPV-AHEAD study, and resulted in the ideal use of
FFPE tissue blocks without extensive manipulation.
Due to the different nature of the routine work performed in histology laboratories, it was
essential to train each collecting center in preventing cross-contamination among the different
FFPE blocks during their processing. Before starting to process the FFPE blocks, each histology
laboratory received a test panel comprised of 25 alternate HPV-positive and HPV-negative
FFPE blocks. To avoid the use of human material and to have unlimited source, the test panel
included FFPE skin tissue of wild-type or HPV 16 E6/E7 transgenic mice. Sections were gener-
ated in the histology laboratories blinded to the HPV result and shipped to IARC for HPV gen-
otyping. Only after performing the quality test for the generation of sections with acceptable
results, each collecting center was allowed to start processing FFPE HNC tissue blocks.
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The protocol also described several procedures to minimize and monitor possible cross-
contamination among the different FFPE (see S1 Fig). For instance, we included empty or
blank paraffin blocks that were processed together with cancer specimens. Subsequently, sec-
tions from human tissue and empty paraffin were analyzed blinded to the DNA content.
Pathology review
The HPV-AHEAD study implied to retrieve cases from archives of European and Indian
hospitals. Although all the HNC tissues were already subjected to histological diagnosis, they
were re-analysed in the context of the HPV-AHEAD study. A panel of six pathologists with a
regional balance was created. The panel established the general criteria for a standardized
histological review (S2 Fig) and generated an online pathology evaluation form (S3 Fig).
Importantly, the slides of the FFPE were digitalized with an Leica SCN400 digital scanner to
20x magnification in the central lab at IARC blind to all pathologists and a database contain-
ing all digital images of the tissue sections was generated to enable all members of the panel
Fig 1. Schematic representation of the sectioning procedures.
https://doi.org/10.1371/journal.pone.0184520.g001
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Fig 2. Detailed description of the sectioning procedures.
https://doi.org/10.1371/journal.pone.0184520.g002
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(i) to simultaneously access the digital images and (ii) to work online from any location in
the world.
Pilot study on the pathology form. From the 14 items included in the histopathology
evaluation form, four were selected to be explored between the first and last sections and
between pathologists’ reviews in a pilot study of 355 cases in order to validate the form by
assuring the presence of the targeted tissue, identifying other tissues that could contaminate
the results and validly assessing the quality of the tissue. Those were: quality of tissue (satisfac-
tory, unsatisfactory, sub-optimal), percentage of invasive carcinoma (0%, <10%, 10–50%, 50–
90%, > 90%), percentage of tumor necrosis (0%, <10%, 10–50%, >50%) and presence of nor-
mal epithelium (absent, present). Indeed, optically normal mucosa may carry HPV and could
contaminate or give false information regarding HPV types. For example, when multiple HPV
types are detected in a PCR from a piece of tissue with tumor and normal or displastic epithe-
lium, by means of laser-microdissection it is possible to demonstrate that tumor harbours one
HPV type, and benign mucosa other [10]. The specimens were distributed over six patholo-
gists so to guarantee that all HNC were analyzed by at least two pathologists, who used the con-
sensus histopathology evaluation form.
Statistical analyses of the pathology review
Data were analyzed with STATA version 13.1. The main diagnoses of the pathologists were
presented as frequencies to the selected items stratified by section (first or last) and pathologist.
The differences of diagnoses between type of tissue (biopsy or surgical specimen) were
explored by Pearson’s chi-square test or Fisher’s exact test when appropriate. Statistical signifi-
cance for all the analyses was set at the 0.05 level. Concordance percent and kappa statistics
were calculated to evaluate the agreement intra-pathologist (i.e. between reading of first and
last sections done by the same pathologist) and inter-pathologist (i.e. between reading of
first section of pathologist 1 and 2). The Kappa statistic characterization was established as fol-
lowing: <0: No agreement; 0–0.20: slight agreement; 0.21–0.40: fair agreement; 0.41–0.60:
moderate agreement; 0.61–0.80: substantial agreement; 0.81–1.0: almost perfect agreement.
Prevalence adjusted bias adjusted kappa (Pabak) statistic was explored when Kappa was not
valid (i.e. when there was an unbalanced distribution of the cell counts in the 2x2 tables. Pabak
statistic may be explored when high percentages of concordances (>80%) but low kappas are
observed). McNemar test p-value was also calculated to evaluate the distribution among the
discordant cases.
Ethical clearance for the investigations reported in this study was obtained from the Institu-
tional Ethical Committees of MGIMS, Sevagram, India and IARC, Lyon, France. Study
implied the use of archival material only, and it did not envisage any contact with the patients.
Adequate measures to ensure data protection, confidentiality, patients’ privacy and anonymi-
zation were taken into account. No informed consent was available due to the retrospective
design of the study and the large proportion of deceased and untraceable patients.
Results
Sectioning and processing of the blocks
In Europe, the HPV-AHEAD consortium retrieved approximatively 5000 FFPE HNC from 44
hospital archives, while in India 3000 FFPE HNC were retrieved in three rural and three urban
hospitals. They were distributed for processing to six different histology laboratories from
France, Belgium, Italy, Spain and India. As first step, each histology laboratory received the
test panel of HPV-positive and HPV-negative FFPE tumor blocks containing skin tissue of
wild-type or HPV 16 E6/E7 transgenic mice together with the detailed protocol for sectioning
FFPE blocks sectioning pathology protocol
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and for preventing cross-contamination of the specimens (see S1 Fig). Sections were all sent to
the central lab of the study at IARC for HPV testing. Sections generated in four histology labo-
ratories did not show any sign of cross-contamination (i.e. the results of tested cases perfectly
matched the panel), while two centers required further instructions and support to implement
the strict cutting procedure in their routine histology laboratories. In particular, the centers
were asked to wash the sectioning platform and microtome blade extensively with DNA
cleaner and 70% ethanol and wear a fresh clean lab coat and face mask (see S1 Fig). The second
attempt resulted in the generation of high quality sections.
After completion of the training phase, each center processed the FFPE blocks according to
the HPV-AHEAD protocols and sections were sent to the different laboratories for additional
analysis. The sectioning of all FFPE tissue blocks was completed in the following histology lab-
oratories: (i) European Institute of Oncology (n = 1075); (ii) University of Antwerp (n = 1084);
(iii) Catalan Institute of Oncology (n = 1364); (iv) IARC (n = 1524) and (v) RGCB (n = 389).
HPV genotyping was performed blinded to the anatomical site by a very sensitive Luminex-
based assay at IARC [11, 12]. Although the assay is not considered the gold-standard, it has
been validated in comparative studies in which specimens were HPV genotyped with other
broadly used assays, i.e. GP5+/6+ [12, 13] and linear array (Roche Diagnostics) [14] and the
results clearly showed that the Luminex assay is more sensitive than the assays mentioned
above. This feature is crucial, in particular when poor quality DNA is analysed, as fragmented
DNA extracted from FFPE tissue blocks [15], as in this study. Moreover, the assay, in addition
to 21 HR HPV types, detects the beta-globin gene, which is used as tool to evaluate the DNA
quality. In the majority of the centers we did not detect any beta-globin positivity in the empty
paraffin blocks that were processed after every tenth FFPE HNC specimens. However, in two
centers (IARC and RGCB), weak beta-globin positivity was detected in less than 5/147 and 2/
39 of the empty paraffin blocks, respectively. Those centers were then informed and asked to
follow strictly the protocol and process a smaller number of specimens per day. Most impor-
tantly, no HPV DNA was found in sections from empty paraffin blocks generated in any his-
tology laboratories of HPV-AHEAD consortium. In addition, the generated sections were
successfully used for the other laboratory analyses, including IHC staining, detection of HR
HPV RNA and histology.
Pilot study on the pathology review of the cases
The analysis of the 355 HNC histopathology evaluation forms showed that most of samples
(88.7%) were biopsies and 11.0% surgical pieces (for one sample the type of tissue was not
recorded). For 75.5% of the samples, S1&S31 could be evaluated (i. e. there was enough tissue
for complete sectioning). This percentage was higher in surgical pieces than biopsies (94.8% vs
73.0%, p = 0.004). Most biopsies (86%) were small with a median size of 7 mm. However, on
average 86% of samples were considered satisfactory in both first and last sections irrespective
of being a biopsy or a surgical piece. More than 60% of the samples showed>50% of invasive
carcinoma in the section. Substantial necrosis (>50%) was present in less than 2% of the sam-
ples, and thus should not affect the quality of molecular analyses. Normal epithelial components
were present in approximately 61% of the samples. This could be checked to justify discordance
between biomarkers (e.g. cases positive for HPV DNA but negative for p16INK4a). Inter-pathol-
ogist (i.e. between diagnoses of pathologists 1 and 2) differences in the diagnoses targeted to val-
idate the form between biopsies and surgical pieces were explored. However, the results were
inconsistent (data not shown), probably due to the small number of surgical pieces.
The results of the intra-pathologist (i.e. between diagnoses of first and last slides) and inter-
pathologist concordance analyses of this pilot are shown in Table 1. Concordance intra-
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pathologist was almost perfect for the diagnoses targeted to validate the form. Concordance
for diagnosis of tissue quality, percentage of invasive carcinoma, percentage of tumoral necro-
sis and presence of normal epithelium was very high (percentage of concordance above 92%
and kappa statistics above 0.85, Table 1).
The concordance inter-pathologist was substantial for the diagnosis of tissue quality (satis-
factory, unsatisfactory, sub-optimal): Percentage of concordance of 86%, kappa 0.34 (pabak
0.72). In contrast, the concordance in the diagnosis of percentage of invasive carcinoma was
low: 37%, kappa 0.11; when grouping the diagnoses of percentage of invasive carcinoma
(<50%,>50%) the concordance slightly improved: 67%, kappa 0.25. The concordance in diag-
nosis of percentage of tumoral necrosis was fair: 61%, kappa 0.25. In this case, when grouping
Table 1. Concordance of selected diagnoses of 355 HNC cases included in the pathology review by slide and pathologist.
Histological characteristics First reading
(Pathologist 1)
Review (Pathologist 2) Inter-pathologist concordance*





p-valuen % n % n % n %
Quality of tissue 86.1 0.34 (<0.001) 0.72 0.86
Satisfactory 308 86.8 304 85.6 308 86.8 307 86.5
Unsatisfactory 25 7.0 34 9.6 25 7.0 30 8.5
Sub-optimal quality 15 4.2 10 2.8 20 5.6 17 4.8
% Intra-pathologist concordance 96.8 96.6
Kappa (p-value) 0.85 (<0.001) 0.86 (<0.001)
McNemar test p-value 0.03 0.31
Percentage of invasive carcinoma 36.5 0.11 (<0.001) NA 0.11
0% 12 3.4 15 4.2 11 3.1 17 4.8
<10% 32 9.0 27 7.6 31 8.3 30 8.5
10–50% 64 18.0 61 17.2 64 18.0 61 17.2
50–90% 118 33.2 115 32.4 157 44.2 152 42.8
> 90% 97 27.3 95 26.8 67 18.9 57 16.1
% Intra-pathologist concordance 91.9 93.3
Kappa (p-value) 0.89 (<0.001) 0.90 (<0.001)
McNemar test p-value 0.53 0.07
Percentage of tumoral necrosis 60.7 0.25 (<0.001) 0.21 0.18
0% 189 53.2 185 52.1 216 60.9 208 58.6
<10% 86 24.2 79 22.3 74 20.9 68 19.2
10–50% 27 7.6 29 8.2 29 8.2 30 8.5
>50% 7 2.0 8 2.3 5 1.4 5 1.4
% Intra-pathologist concordance 96.6 97.4
Kappa (p-value) 0.94 (<0.001) 0.95 (<0.001)
McNemar test p-value 0.27 0.34
Normal epithelium 73.6 0.44 (<0.001) 0.47 0.06
Absent 138 38.9 137 38.6 123 34.7 120 33.8
Present 207 58.3 202 56.9 228 64.2 224 63.1
% Intra-pathologist concordance 96.7 96.2
Kappa (p-value) 0.93 (<0.001) 0.92 (<0.001)
McNemar test p-value 0.37 0.78
NA: Not applicable. For some variables the cases do not sum 355 because of missing values or slides not evaluated.
*Calculated by comparing the first slides’ diagnoses
https://doi.org/10.1371/journal.pone.0184520.t001
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the diagnoses (<50%, >50%) the concordance improved substantially: 98.3%, kappa 0.44
(pabak 0.97). Finally, the concordance in diagnosis of presence of normal epithelium was mod-
erate: 74%, kappa 0.44.
Discussion
To the best of our knowledge, this is the first attempt to develop and report a standardized sec-
tioning and histopathology review protocol for optimizing the use of HNC paraffin blocks
in multi-centric molecular epidemiological studies. Moreover, this protocol could also be
extended for other cancer sites in which cross contamination and precise diagnosis are crucial.
An equivalent histopathology protocol for breast cancer in situ has been described [16].
Another study identified aspects that could affect next generation sequencing regarding the
tissue quality in solid tumors [17]. Also, a study on non-small cell lung cancer samples demon-
strated considerable variation in tumor nuclei percentage between pathologists and conse-
quently proposed a new system for automated tumor annotation and percentage tumor nuclei
measurement [18]. We developed a thorough protocol for sectioning in order to avoid cross-
contamination among the different blocks to be performed simultaneously in different centres
of different countries. All the centers had good results in the quality control, confirming the
validity and wide applicability of our protocol that it could be easily established in different his-
tology laboratories from low and high income countries. With the increase of technological
developments that allow running a wide range of biomarkers in a single sample, the need of
optimized and standardized protocols such as the one herein presented is warranted. One
could argue that tissue microarrays may be a more efficient way to optimize the paraffin blocks
[19]. However, its applicability in international multicentric studies is very limited since there
are many legal constraints to irreversibly manipulate the blocks and moreover, the risk of con-
tamination is high.
The assessment of the histopathology evaluation form developed by an international panel
of pathologists confirmed its validity to assure the presence of the targeted tissue, identify
other tissues that could contaminate the diagnosis and assess the quality of the tissue. The con-
cordance between first and last slides was very high, confirming no loss of targeted tissue
throughout the different sections. Most cases were considered satisfactory regardless of the
type of sample (i.e. biopsy or surgical piece). The concordance between pathologists’ diagnoses
was fair to high and improved when grouping the categories of the items to more general diag-
noses. Macrodisssection was not among the required procedures in our protocol and thus, the
objective of assessing percentage of invasive carcinoma did not need to be as accurate as in
other studies [18]. Thus, the obtained estimates of the amount of tumor tissue to confirm that
tumoral DNA was not diluted with other tissues (normal, inflammatory, dysplastic, etc) were
fair enough for pursuing our goals. Moreover, a database containing all digital images of the
tissue sections was generated to enable all members of the panel to simultaneously access the
digital images and to work online from any location in the world.
It is expected that such standardized and validated sectioning and histopathology protocol
can be adapted to any multi-centric study with similar aims as the ones observed in the
HPV-AHEAD study. Less stringent protocols using this scheme as backbone could also be
applied to other molecular studies, including high-throughput and next generation genomic
studies. The versatility of the histopathology evaluation form, which was developed specifically
for the study and not for clinical practice, allows for a wide range approach studies. The proto-
col as presented can be easily performed in any location in the world. The herein developed
procedure for simultaneous on-line revision of the samples facilitates and enhances the estab-
lishment of international panel of experts of any pathology.
FFPE blocks sectioning pathology protocol
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In an era of increasing technological developments that allow running a wide range of bio-
markers in a single sample, as well as of increase of international collaborative projects to
tackle and provide important insights of a wide range of diseases, we believe that the sectioning
and histopathology protocol that we have developed and validated in the context of the HPV
AHEAD study may be of great interest and applicability.
Supporting information
S1 Fig. Summary of precautions to be employed during sectioning paraffin blocks for HPV
analysis.
(TIF)
S2 Fig. Revised pathology evaluation form.
(TIF)
S3 Fig. Screenshot of the website pathology evaluation form.
(TIF)
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Tommasino.
Validation: Tarik Gheit.
Visualization: Marisa Mena, Laia Alemany, Massimo Tommasino.
Writing – original draft: Marisa Mena.
Writing – review & editing: Marisa Mena, Belen Lloveras, Sara Tous, Johannes Bogers, Fausto
Maffini, Nitin Gangane, Rekha Vijay Kumar, Thara Somanathan, Eric Lucas, Devasena
Anantharaman, Tarik Gheit, Xavier Castellsagué, Michael Pawlita, Silvia de Sanjosé, Laia
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